PTPRC and discoid lupus erythematosus: Ji et al.’s study of JP and PF- mediated inhibition of IRAK1 is of particular interest to our group, as we recently identified IRAK1 as a potential treatment target in CD45+ immune cells in discoid lupus erythematosus (DLE) lesional skin using spatial transcriptomics (Haddadi et al. submitted, GSE182825).